By Tom Salemi
Venture capitalists have spent the past decade backing a series of companies developing devices to treat chronic obstructive pulmonary disease....
Rox Gets Blood Pumping in COPD
Rox Medical is taking an unusual approach to treating COPD by introducing a vascular device that increases oxygen delivery to tissue and cardiac output. The potential has investors' hearts racing as well.
More from Global Vision
• By
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
• By
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
• By
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
• By
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
More from In Vivo
• By
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.